TITLE

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

AUTHOR(S)
Sin, D. D.; Wu, L.; Anderson, J. A.; Anthonisen, N. R.; Buist, A. S.; Burge, P. S.; Calverley, P. M.; Connett, J. E.; Lindmark, B.; Pauwels, R. A.; Postma, D. S.; Soriano, J. B.; Szafranski, W.; Vestbo, J.
PUB. DATE
December 2005
SOURCE
Thorax;Dec2005, Vol. 60 Issue 12, p992
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in chronic obstructive pulmonary disease (COPD). However, their effect on mortality is unknown. Methods: A pooled analysis, based on intention to treat, of individual patient data from seven randomised trials (involving 5085 patients) was performed in which the effects of inhaled corticosteroids and placebo were compared over at least 12 months in patients with stable COPD. The end point was all-cause mortality. Results: Overall, 4% of the participants died during a mean follow up period of 26 months. Inhaled corticosteroids reduced all-cause mortality by about 25% relative to placebo. Stratification by individual trials and adjustments for age, sex, baseline post-bronchodilator percentage predicted forced expiratory volume in 1 second, smoking status, and body mass index did not materially change the results (adjusted hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.55 to 0.96). Although there was considerable overlap between subgroups in terms of effect sizes, the beneficial effect was especially noticeable in women (adjusted HR 0.46; 95% CI 0.24 to 0.91) and former smokers (adjusted HR 0.60; 95% CI 0.39 to 0.93). Conclusions: Inhaled corticosteroids reduce all-cause mortality in COPD. Further studies are required to determine whether the survival benefits persist beyond 2-3 years.
ACCESSION #
19120637

 

Related Articles

  • Inhaled cortico-steroids and COPD exacerbations.  // Infectious Disease Alert;Apr2010 Primary Care, p8 

    The article discusses research done by R. Agarwal and colleagues on inhaled corticosteroids versus placebo for preventing chronic obstructive pulmonary disease (COPD) exacerbations, published in a 2010 issue of "Chest."

  • Safety of Inhaled Budesonide. Christensson, Camilla; Thorén, Anders; Lindberg, Bengt // Drug Safety;2008, Vol. 31 Issue 11, p965 

    Inhaled corticosteroid (ICS) therapy is central to the long-term management of asthma and is extensively used in the management of chronic obstructive pulmonary disease (COPD). While administration via inhalation limits systemic exposure compared with oral or injected corticosteroids and,...

  • Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in COPD. Rees, P. John // Evidence Based Medicine;Jun2009, Vol. 14 Issue 3, p8 

    The article offers information on the advantages and disadvantages of inhaled corticosteroid (ICS) therapy in treating patients with stable chronic obstructive pulmonary disease (COPD). It notes that inhaled cortecosteroids with placebo or inhaled medications can contribute to mortality,...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

  • Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. South, Mike // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p23 

    This article focuses on a study that deals with an early intervention with budesonide in mild persistent asthma. A randomized, double-blind clinical trial in 7241 patients in 32 countries was conducted to assess the effects of budesonide in patients who had mild persistent asthma for less than 2...

  • Daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma: COMMENTARY. Ramey, John T.; Ledford, Dennis // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p60 

    This article comments on a clinical study in which daily corticosteroids were not better than as-needed corticosteroids in mild persistent asthma. The use of as-needed inhaled corticosteroids (ICSs) eventually may be shown to be an alternative in the treatment of mild persistent asthma, but...

  • TIOTROPIUM FOR COPD.  // Bandolier;May2006, Vol. 13 Issue 5, p5 

    This article discusses findings of a study which investigated the use of tiotropium for treating chronic obstructive pulmonary disease (COPD). A chart is presented that summarizes results of trials which compared tiotropium with placebo, with outcomes of exacerbations and of hospital admissions....

  • Inhaled corticosteroids and COPD exacerbations.  // Clinical Cardiology Alert;Apr2010 Primary Care Supplement, Vol. 15 Issue 4, p8 

    The article discusses research on the effectiveness of inhaled corticosteriods compared with placebo in preventing chronic obstructive pulmonary disease (COPD) exacerbations by R. Agarwal and colleagues published in a 2010 issue of "Chest."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics